Latest news with #HRMY
Yahoo
22-07-2025
- Business
- Yahoo
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
PLYMOUTH MEETING, Pa., July 22, 2025--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit View source version on Contacts Harmony Biosciences Investor Contact: Brennan Doyle484-539-9700bdoyle@ Harmony Biosciences Media Contact: Cate McCanless202-641-6086cmccanless@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Harmony Biosciences Holdings, Inc. (HRMY), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.53%. For the most recent quarter, Harmony Biosciences was expected to post earnings of $0.78 per share, but it reported $0.59 per share instead, representing a surprise of 32.20%. For the previous quarter, the consensus estimate was $0.74 per share, while it actually produced $0.85 per share, a surprise of 14.86%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for Harmony Biosciences. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Harmony Biosciences currently has an Earnings ESP of +19.75%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. Harmony Biosciences Holdings, Inc. (HRMY) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy). While there are numerous reasons why the stock of this company is a great growth pick right now, we have highlighted three of the most important factors below: Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for Harmony Biosciences is 11.7%, investors should actually focus on the projected growth. The company's EPS is expected to grow 22.5% this year, crushing the industry average, which calls for EPS growth of 19.1%. Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for Harmony Biosciences is 10%, which is higher than many of its peers. In fact, the rate compares to the industry average of -4.7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 25.7% over the past 3-5 years versus the industry average of 4.1%. Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for Harmony Biosciences have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.2% over the past month. Harmony Biosciences has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination indicates that Harmony Biosciences is a potential outperformer and a solid choice for growth investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $70.00. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The company reported strong fiscal Q1 2025 results, with net revenue for WAKIX (pitolisant) in narcolepsy reaching $184.7 million for the quarter, reflecting a 20% year-over-year growth. It projects 2025 net revenue to be in the range of $820 to $860 million. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also experienced a 19% year-over-year increase in net income, building on four consecutive years of profitability. It increased its cash and investments to more than $600 million on the balance sheet. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
24-06-2025
- Business
- Yahoo
Needham Reiterates a Buy Rating on Harmony Biosciences (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on June 6 and set a price target of $49.00. The analyst based the rating on the company's promising developments and data, citing the preclinical data for BP1.15205. Presented at the SLEEP 2025 conference, the data highlights significant clinical activity in an orexin/ataxin-3 mouse model, with no noted safety concerns and a wide therapeutic index. This is a positive factor for the drug's efficacy, as it points towards the potential for nearly complete wakefulness at low doses. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The analyst further supported the optimistic rating for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) with comparative data from other compounds, such as ORX750 and TAK-861, which demonstrated promising results with considerable wakefulness and a reduction in cataplexy episodes. All these factors contribute to a bullish outlook for the company's pipeline for addressing unmet needs in sleep disorders. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
